Biologics are complex, large molecule drugs based on proteins which have a therapeutic effect.

Biologics are part of what Syncona calls the “First Wave” of technologies in healthcare and are dominated by large pharmaceutical companies. Syncona targets innovative technologies in the space and our company Anaveon is a strong example of this.

Anaveon is a pre-clinical phase start-up based in Switzerland that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology.